{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:18:53Z","timestamp":1789175933739,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010041","name":"Tianjin Science and Technology Committee","doi-asserted-by":"publisher","award":["17ZXMFSY00190"],"award-info":[{"award-number":["17ZXMFSY00190"]}],"id":[{"id":"10.13039\/501100010041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Kanglaite(KLT), a type of Chinese medicine preparation, is considered as an adjuvant therapeutic option for malignant cancer treatment. This study aimed to systematically investigate the efficacy and safety of the combination of KLT and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for the treatment of stage III\/IV non-small cell lung cancer.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Randomized controlled trials (RCTs) that compared KLT plus EGFR-TKI with EGFR-TKI alone for the treatment of stage III\/IV non-small cell lung cancer were reviewed. Literature searches (up to July 10, 2021) were performed on PubMed, Web of Science, Cochrane Library, Embase, <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, China National Knowledge Infrastructure (CNKI), Wanfang Database, and the Chinese Scientific Journal Database. Two researchers independently assessed the risk of bias with the tool of Cochrane Collaboration. RevMan 5.3.0 was used in the analysis of the included trial data.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> 12 RCTs recruiting 1,046 patients with stage III\/IV NSCLC were included. Results showed that compared with EGFR-TKI alone, KLT plus EGFR-TKI significantly increased the disease control rate (DCR) (odds ratio [OR]=3.26; 95% confidence interval [CI]:2.22\u20134.77; <jats:italic>p<\/jats:italic> &amp;lt; 0.00001), the objective response rate (ORR) (OR=2.59; 95% CI:1.87\u20133.58; <jats:italic>p<\/jats:italic> &amp;lt; 0.00001) and Karnofsky performance status (KPS) (OR = 2.76; 95% CI:1.73\u20134.39; <jats:italic>p<\/jats:italic> &amp;lt; 0.00001). Furthermore, patient immunity was enhanced with KLT plus EGFR-TKI. The combined treatment increased the percentage of CD4 + T cells (weighted mean difference [WMD]=5.36; 95% CI:3.60\u20137.13; <jats:italic>p<\/jats:italic> &amp;lt; 0.00001),the CD4+\/CD8 + ratio (WMD = 0.18; 95% CI: 0.08\u20130.27; <jats:italic>p<\/jats:italic> = 0.004), and percentage of NK cells (WMD=4.84; 95% CI: 3.66\u20136.02; <jats:italic>p<\/jats:italic> &amp;lt; 0.00001).With regard to drug toxicity, the occurrence rate of nausea and vomiting was significantly reduced by KLT plus EGFR-TKI (OR=0.37; 95% CI: 0.16\u20130.86; <jats:italic>p<\/jats:italic> = 0.02).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> KLT plus EGFR-TKI was effective in treating stage III\/IV non-small cell lung cancer. Thus, its application in these patients is worth promoting. Additional double-blind, well-designed and multicenter RCTs are required to confirm the efficacy and safety of this treatment.<\/jats:p>","DOI":"10.3389\/fphar.2021.739843","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T04:41:40Z","timestamp":1631508100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III\/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Fanming","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/jcph.191","article-title":"Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western versus Chinese Patients with First-Line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab","volume":"54","author":"Claret","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5497041","DOI":"10.1155\/2020\/5497041","article-title":"Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis","volume":"2020","author":"Dou","year":"2020","journal-title":"Evid. Based Complement. Alternat Med."},{"key":"B3","first-page":"838","article-title":"The Effects of Combination of Coix Seed Extract and Cisplatin on TAM and Expression of HIF-1\u03b1 In Vivo in Lewis Lung Carcinoma","volume":"47","author":"Duan","year":"2018","journal-title":"Iran. J. Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3969\/j.issn.1002-7386.2013.05.021","article-title":"Observation of Kanglaite Injection Combined with Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer","volume":"35","author":"Guo","year":"2013","journal-title":"Hebei Med. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.4103\/jcrt.JCRT_1213_16","article-title":"The Effect of Kanglaite Injection in Combination with Gefitinib versus Gefitinib Alone in Patients with Nonsmall Cell Lung Cancer: A Meta-Analysis","volume":"16","author":"Hailang","year":"","journal-title":"J. Cancer Res. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib Alone versus Gefitinib Plus Chemotherapy for Non-small-cell Lung Cancer with Mutated Epidermal Growth Factor Receptor: NEJ009 Study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"153154","DOI":"10.1016\/j.phymed.2019.153154","article-title":"Kanglaite Injection Plus Platinum-Based Chemotherapy for Stage III\/IV Non-small Cell Lung Cancer: A Meta-Analysis of 27 RCTs","volume":"67","author":"Huang","year":"","journal-title":"Phytomedicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3389\/fphar.2019.00732","article-title":"Chinese Herbal Medicine Combined with EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Jiao","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B10","first-page":"147","article-title":"Effects of Kanglaite Injection Combined with Gefitinib on Inflammatory Factors and Immune Function with Advanced Lung Cancer","volume":"36","author":"Jin","year":"2016","journal-title":"Chin. J. Biochem. Pharmaceuticals"},{"key":"B11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3892\/ol.2021.12907","article-title":"Medicinal Herbs and Bioactive Compounds Overcome the Drug Resistance to Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer","volume":"22","author":"Lee","year":"2021","journal-title":"Oncol. Lett."},{"key":"B12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.14164\/j.cnki.cn11-5581\/r.2020.05.060","article-title":"Evaluation of the Clinical Effect of Gefitinib Tablets Combined with Kanglaite Capsules in the Treatment of Stage \u2162B\/IV Non-small Cell Lung Cancer","volume":"14","author":"Li","year":"2020","journal-title":"Chin. J. Mod. Drug Appl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.21037\/apm-20-616","article-title":"Efficacy and Safety of Kanglaite Injection Combined with First-Line Platinum-Based Chemotherapy in Patients with Advanced NSCLC: a Systematic Review and Meta-Analysis of 32 RCTs","volume":"9","author":"Li","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20193319","article-title":"The Clinical Efficacy and Safety of Kanglaite Adjuvant Therapy in the Treatment of Advanced Hepatocellular Carcinoma: A PRISMA-Compliant Meta-Analysis","volume":"39","author":"Liu","year":"2019","journal-title":"Biosci. Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.601785","article-title":"Unlocking the Mystery of the Therapeutic Effects of Chinese Medicine on Cancer","volume":"11","author":"Liu","year":"","journal-title":"Front. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.572396","article-title":"Comparative Efficacy and Safety of Chinese Herbal Injections Combined with Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis","volume":"11","author":"Liu","year":"","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.bbrc.2012.11.058","article-title":"A Polysaccharide Fraction of Adlay Seed (Coixlachryma-Jobi L.) Induces Apoptosis in Human Non-small Cell Lung Cancer A549 Cells","volume":"430","author":"Lu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3892\/mmr.2016.5985","article-title":"Molecular Inhibition Mechanisms of Cell Migration and Invasion by Coix Polysaccharides in A549 NSCLC Cells via Targeting S100A4","volume":"15","author":"Luo","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e22357","DOI":"10.1097\/MD.0000000000022357","article-title":"Efficacy and Safety of Kanglaite Injection Combined with Chemotherapy for Colorectal Cancer: A Protocol for Systematic Review and Meta-Analysis","volume":"99","author":"Mao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"631170","DOI":"10.3389\/fphar.2020.631170","article-title":"Investigation on the Efficiency of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer with Vinorelbine and Cisplatin Based on Multidimensional Bayesian Network Meta-Analysis","volume":"11","author":"Ni","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.3969\/j.issn.1672-4992.2015.14.11","article-title":"Effect of Gefitinib Combined with KLT Nepalese on the Function and Quality of Life of Non-small Cell Lung Cancer Patients","volume":"23","author":"Ning","year":"2015","journal-title":"MODERN ONCOLOGY"},{"key":"B22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jep.2012.07.025","article-title":"Antitumor Activity and Immunomodulatory Effects of the Intraperitoneal Administration of Kanglaite In Vivo in Lewis Lung Carcinoma","volume":"143","author":"Pan","year":"2012","journal-title":"J. Ethnopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1002\/cncr.31029","article-title":"Lung Cancer Survival in the United States by Race and Stage (2001-2009): Findings from the CONCORD-2 Study","volume":"123","author":"Richards","year":"2017","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-small-cell Lung Cancer (EURTAC): a Multicentre, Open-Label, Randomised Phase 3 Trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","article-title":"Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology","volume":"42","author":"Shah","year":"2019","journal-title":"Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3781\/j.issn.1000-7431.2013.12.003","article-title":"The Effect of Kanglaite Injection in Combination with Gefitinib on Angiogenesis in Mice with Lewis Lung Cancer","volume":"33","author":"Shen","year":"2013","journal-title":"TUMOR"},{"key":"B27","first-page":"76","article-title":"Clinical Observation of Kanglaite InJection Combined with Gefitinib in the Treatment of Non-small Cell Lung Cancer with EGFR Positive in Medium or Late Stage","volume":"4","author":"Shi","year":"2013","journal-title":"Chin. Manipulation Rehabil. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e20683","DOI":"10.1097\/MD.0000000000020683","article-title":"Combination of Traditional Chinese Medicine and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"99","author":"Sui","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA CANCER J. CLIN."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8430","DOI":"10.12659\/MSM.917251","article-title":"Traditional Chinese Medicine Prolongs Progression-free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-small-cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations","volume":"25","author":"Tang","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"B31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.13705\/j.issn.1671-6825.2018.05.042","article-title":"Effects of Kanglaite and Erlotinib Combination on Proliferation and Invasion and JAK2\/STAT3 Signaling Pathway of Lung Cancer A549 Cells","volume":"54","author":"Wang","year":"2019","journal-title":"J. Zhengzhou Univ"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2147\/OTT.S106399","article-title":"Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-small-cell Lung Cancer with Activating EGFR Mutations","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther."},{"key":"B33","first-page":"1631","article-title":"Clinical Trial of Gefitinib Tablets Combined with Kanglaite Capsules in the Treatmentof Stage \u2162B\/\u2163 Non-small Cell Lung Cancer","volume":"33","author":"Wang","year":"2017","journal-title":"Chin. J. Clin. Pharmaco"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8586596","DOI":"10.1155\/2020\/8586596","article-title":"Kanglaite Injection Combined with Chemotherapy versus Chemotherapy Alone for the Improvement of Clinical Efficacy and Immune Function in Patients with Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"2020","author":"Wen","year":"2020","journal-title":"Evid. Based Complement. Alternat Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.12659\/MSM.909719","article-title":"Effects of Kanglaite Injection on Serum miRNA-21 in Patients with Advanced Lung Cancer","volume":"24","author":"Wu","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cam4.2108","article-title":"Traditional Chinese Medicine as a Cancer Treatment: Modern Perspectives of Ancient but Advanced Science","volume":"8","author":"Xiang","year":"2019","journal-title":"Cancer Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.13241\/j.cnki.pmb.2016.19.033","article-title":"Influence of Kanglaite Combined with Gefitinib on Immune Function and Quality of Life of Patients with Advanced Non-small Cell Lung Cancer","volume":"16","author":"Yang","year":"2016","journal-title":"Prog. Mod. Biomed."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.666368","article-title":"Clinical Application of Chinese Herbal Injection for Cancer Care: Evidence-Mapping of the Systematic Reviews, Meta-Analyses, and Randomized Controlled Trials","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.7501\/j.issn.1674-5515.2016.12.027","article-title":"Clinical Study on Kanglaite Injection Combined with Icotinib in Treatment of Non-small Cell Lung Cancer","volume":"31","author":"Yang","year":"2016","journal-title":"Drugs & Clinic"},{"key":"B40","first-page":"930","article-title":"Influence of Kanglaite Plus Gefitinib on Immune Function and Quality of Life in Patients with Advanced Non-small-cell Lung Cancer","volume":"28","author":"Zeng","year":"2014","journal-title":"J. Chin. Pract. Diagn. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3781\/j.issn.1000-7431.2011.01.019","article-title":"Clinical Observation on 78 Cases of Kanglaite Injection Combined with Gefitinib in the Treatment of Advanced Non-small Cell Lung Cancer","volume":"31","author":"Zhang","year":"2011","journal-title":"Tumor"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3969\/j.issn.1672-4992.2014.12.26","article-title":"Clinical Efficacy of Gefitinib Combined with LT in Treatment of Advanced Non-small Cell Lung Cancer","volume":"22","author":"Zhang","year":"2014","journal-title":"MODERN ONCOLOGY"},{"key":"B43","first-page":"1","article-title":"Effects of Kanglaite Injection on the Apoptosis Induced by Gefitinib in Lung Adenocarcinoma A549 Cell Line","volume":"20","author":"Zhao","year":"2015","journal-title":"Chin. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3969\/j.issn.1674-7593.2019.05.001","article-title":"Effects of Gefitinib Combined with Kanglaite Injection on Advanced Lung Cancer in Older Patients","volume":"40","author":"Zhao","year":"2019","journal-title":"Int. J. Geriatr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.739843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T04:41:53Z","timestamp":1631508113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.739843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":44,"alternative-id":["10.3389\/fphar.2021.739843"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.739843","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"article-number":"739843"}}